Juberahamad Rajjak Attar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juberahamad Rajjak Attar has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Mohammad Yousuf Ansari
MM College of Pharmacy, Maharishi Markandeshwar (Deemed To Be University), Ambala, India
2 shared publications - Mohini Mondal
Department of Pharmaceutical Technology, JIS University, Agarpara, Kolkata, India
2 shared publications - Sabina Yasmin
King Khalid University
2 shared publications - Sadique Hussain
Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India
2 shared publications - Sumel Ashique
School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, India
2 shared publications - Anas Islam
Faculty of Pharmacy, Integral University, Lucknow, India
1 shared publication
Latest Publications
- 21 April 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (5) , 2873-2888
Safety and efficacy of COVID-19 vaccines in pregnant and lactating women: a comprehensive review
Breastfeeding plays a critical role in providing essential nutrients and antibodies that enhance the health of new-borns and infants, supporting their immune systems and overall growth and development. Healthcare professionals, universally recommend breastfeeding for the first six months of an infant’s life, in conjunction with an appropriate complementary diet. However, the COVID-19 pandemic has understandably raised concerns among lactating mothers and pregnant women regarding the risks of infection and vaccine safety. Therefore, it is essential to carefully evaluate the potential dangers of COVID-19 transmission within this vulnerable population especially when considering vaccination for pregnant and breastfeeding women. Encouragingly, the United States Food and Drug Administration has granted approval for the use of two COVID-19 vaccines namely, Pfizer-BioNTech COVID-19 and Moderna COVID-19 to contain the spread of the COVID-19 virus. Both vaccines have been approved for administration in pregnant and breastfeeding women, providing much-needed reassurance to those with concerns about vaccine safety. It is important to recognize that the benefits of vaccination for both the mother and the infant far outweigh the risks associated with COVID-19 infection. Therefore, lactating mothers should view vaccination as a vital measure to protect themselves and their infants from the virus. In addition to elaborating on the successes of safety and effectiveness, this review is unique that it also includes current and newly updated evidence published between 2020 and 2025, comprehensively discussing on several newer vaccine platforms together with recent viral variants. Furthermore, it synthesizes information on the transfer of transplacental and a breast-milk antibody that outlines a clear evidence-gap that may direct further research within pregnant and lactating populations. Graphical abstract The alternative text for this image may have been generated using AI.
- 21 April 2026
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (5) , 2873-2888
Safety and efficacy of COVID-19 vaccines in pregnant and lactating women: a comprehensive review
Breastfeeding plays a critical role in providing essential nutrients and antibodies that enhance the health of new-borns and infants, supporting their immune systems and overall growth and development. Healthcare professionals, universally recommend breastfeeding for the first six months of an infant’s life, in conjunction with an appropriate complementary diet. However, the COVID-19 pandemic has understandably raised concerns among lactating mothers and pregnant women regarding the risks of infection and vaccine safety. Therefore, it is essential to carefully evaluate the potential dangers of COVID-19 transmission within this vulnerable population especially when considering vaccination for pregnant and breastfeeding women. Encouragingly, the United States Food and Drug Administration has granted approval for the use of two COVID-19 vaccines namely, Pfizer-BioNTech COVID-19 and Moderna COVID-19 to contain the spread of the COVID-19 virus. Both vaccines have been approved for administration in pregnant and breastfeeding women, providing much-needed reassurance to those with concerns about vaccine safety. It is important to recognize that the benefits of vaccination for both the mother and the infant far outweigh the risks associated with COVID-19 infection. Therefore, lactating mothers should view vaccination as a vital measure to protect themselves and their infants from the virus. In addition to elaborating on the successes of safety and effectiveness, this review is unique that it also includes current and newly updated evidence published between 2020 and 2025, comprehensively discussing on several newer vaccine platforms together with recent viral variants. Furthermore, it synthesizes information on the transfer of transplacental and a breast-milk antibody that outlines a clear evidence-gap that may direct further research within pregnant and lactating populations. Graphical abstract The alternative text for this image may have been generated using AI.
- 3 January 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 690, 126545
Oleosomes as emerging Next-Generation carrier for topical drug delivery
- 3 January 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 690, 126545
Oleosomes as emerging Next-Generation carrier for topical drug delivery